Table 2.
Ongoing clinical trials on ALS/MND in Australia.
| Clinical trial title | Description | Status | Recruiting |
|---|---|---|---|
| Cu(II)ATSM | A small molecule that is able to deliver copper to cells containing damaged mitochondria [29] | Phase 2/3 | Yes |
| EMERALD | Cannabis Based Medicine Extract (CannTrust CBD Oil) [30] | Phase 3 | Yes |
| Communication and Assistive Technology (CAT) | Assessment and intervention within CAT [31] | Yes | |
| Oral levosimendan (ODM-109) | Restore respiratory function in patients with ALS [32] | Phase 3 | Yes |
| Triumeq | Antiretroviral therapy [33] | Phase 3 | Not yet |
| Tecfidera | Reduce neuroinflammation and increase the levels of Regulatory T cells (Tregs) in humans [34] | Phase 2 | Completed |
| BIIB067 (Tofersen) | Antisense therapeutic specifically targeted SOD1 mutation in ALS patients [35]. | Phase 3 | Yes |
| CNM-Au8 | An oral, gold nanocrystal liquid suspension. CNM-Au8 can support bioenergetic cellular reactions and assist to remove the toxic byproducts of cellular metabolism that may induce motor neurons breakdown in ALS [36]. | Phase 2 | Yes |
| ALS-205/PMX205 | Potent non-competitive inhibitors of complement C5a receptor 1 (C5aR1) [37] | Phase 1 | Not yet |
Sources can be found from website of https://www.mndsa.org.au/Discover-our-research/Latest-research/Clinical-trials.aspx.